HeXun Biosciences Co., Ltd. (TPEX:6986)

HeXun Biosciences Income Statement

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	293.23	286.42	130.57	49.47	-
Revenue Growth (YoY)	2.38%	119.36%	163.94%	-	-
Cost of Revenue	26.95	25.75	16.84	4.86	-
Gross Profit	266.28	260.67	113.73	44.61	-
Selling, General & Admin	49.09	39.57	33.14	14.23	5.95
Research & Development	99.18	65.37	53.22	39.36	44.71
Operating Expenses	148.27	104.94	86.36	53.59	50.66
Operating Income	118.01	155.73	27.37	-8.98	-50.66
Interest Expense	-1.11	-1.18	-1.85	-1.64	-1.57
Interest & Investment Income	6.75	4.41	2.79	0.46	0.03
Currency Exchange Gain (Loss)	-	-0.79	0.53	0.02	-
Other Non Operating Income (Expenses)	2.29	3.3	4.7	4.93	9.01
EBT Excluding Unusual Items	125.93	161.48	33.54	-5.21	-43.19
Gain (Loss) on Sale of Assets	-	-0.01	-0.05	0.02	0.2
Pretax Income	125.93	161.47	33.49	-5.19	-42.99
Income Tax Expense	14.02	14.25	-	-	-
Net Income	111.91	147.22	33.49	-5.19	-42.99
Net Income to Common	111.91	147.22	33.49	-5.19	-42.99
Net Income Growth	-23.99%	339.62%	-	-	-
Shares Outstanding (Basic)	46	46	45	38	31
Shares Outstanding (Diluted)	46	46	45	38	31
Shares Change (YoY)	0.04%	1.61%	20.81%	22.92%	-
EPS (Basic)	2.43	3.20	0.74	-0.14	-1.41
EPS (Diluted)	2.43	3.20	0.74	-0.14	-1.41
EPS Growth	-24.06%	332.90%	-	-	-
Free Cash Flow	140.23	83.63	22.42	10	-35.5
Free Cash Flow Per Share	3.04	1.82	0.49	0.27	-1.16
Gross Margin	90.81%	91.01%	87.10%	90.18%	-
Operating Margin	40.24%	54.37%	20.96%	-18.15%	-
Profit Margin	38.16%	51.40%	25.65%	-10.49%	-
Free Cash Flow Margin	47.83%	29.20%	17.17%	20.22%	-
EBITDA	146.95	175.88	43.12	2.58	-41.87
EBITDA Margin	50.11%	61.41%	33.03%	5.21%	-
D&A For EBITDA	28.94	20.15	15.75	11.56	8.8
EBIT	118.01	155.73	27.37	-8.98	-50.66
EBIT Margin	40.24%	54.37%	20.96%	-18.15%	-
Effective Tax Rate	11.13%	8.82%	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.